Compare Micron Technology, Inc. (MU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs GeneDx Holdings Corp — how do they compare? Micron Technology, Inc. trades at $1,029 (market cap $1.17T), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Micron Technology, Inc. is far larger — about 579.2× GeneDx Holdings Corp's market cap, and Micron Technology, Inc. pays a 0.06% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and GeneDx Holdings Corp for 19 Days on average.
| MU | WGS | |
|---|---|---|
Market Cap | $1.17T | $2.02B |
Volume | 29,425,906 | 734,640 |
Sector | Technology | Health |
52-Week High | $1.21K | $167.51 |
52-Week Low | $181.60 | $34.51 |
Typical Hold Time | 48 Days | 19 Days |
Enterprise Value | $1.13T | $2.05B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,035.84, down 4.79% on the day but maintains strong technical momentum with a bullish moving average signal. The company demonstrates exceptional fundamental strength with 63.8% net income margin and 91.77% ROE, supported by three consecutive quarterly earnings beats. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility into sustained AI-driven memory demand growth.
Outlook remains positive with analyst consensus target of $1,590 representing 53% upside potential. Key opportunities include AI memory market expansion and supply constraints through 2028, while risks center on cyclical industry dynamics and potential growth deceleration. The stock's current valuation at 13.94 P/E appears reasonable given growth trajectory.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
